New anesthesia combo aims to keep elderly patients safer during ERCP
NCT ID NCT07584902
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at which combination of sedative and painkiller drugs works best to prevent low oxygen levels and low blood pressure in older adults (age 60+) undergoing a procedure called ERCP for bile duct or pancreas problems. About 236 participants will be randomly assigned to receive either propofol or ciprofol as the sedative, and either sufentanil or es-ketamine as the painkiller. The goal is to find the safest anesthesia approach for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 236 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 60 years old. * ASA II-III level. * BMI\<30kg/m2. * Patients who require elective therapeutic ERCP. * Voluntarily participate in this study and sign an informed consent form. If the subject is unable to read and sign the informed consent form due to reasons such as lack of capacity, their guardian needs to act as a proxy for the informed process and sign the informed consent form. If the subject lacks the ability to read the informed consent form (such as illiterate subjects), a witness is required to witness the informed process and sign the informed consent form. Exclusion Criteria: * Previous anatomical changes in the gastrointestinal tract, delayed gastric emptying, and gastric outlet obstruction. * Coagulation dysfunction or tendency towards nosebleeds. * Combined severe heart disease (coronary heart disease, myocardial infarction, congestive heart failure, left ventricular ejection fraction\<40%, tachyarrhythmia) * Have a history of allergies to relevant anesthetic drugs in the past. * Severe pulmonary diseases (severe asthma attacks, respiratory failure, severe chronic obstructive pulmonary disease, severe interstitial lung disease, large pleural effusion, severe pulmonary arterial hypertension, etc.). * Existing upper respiratory tract infection (within one week). * Uncontrolled severe hypertension. * Patients with increased intracranial pressure; Cerebral hemorrhage, intracranial space occupying lesions, acute phase of traumatic brain injury. * Glaucoma and significant increase in intraocular pressure. * Untreated or inadequately treated patients with hyperthyroidism. * Serious liver and kidney diseases. * Known neurological and psychiatric disorders (Parkinson's disease, epilepsy, or schizophrenia). * Difficult airway: The anesthesiologist assessed the presence of difficult airway before surgery. * Vulnerable groups other than the elderly/illiterate, including those with mental illness, cognitive impairment, critically ill patients, pregnant women, etc.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Biliary and pancreatic diseases are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.